Finerenone

Finerenone
Clinical data
Trade names	Kerendia
Other names	BAY 94-8862
AHFS/Drugs.com	Monograph
MedlinePlus	a621038
License data	US DailyMed: Finerenone;
Pregnancy; category	AU: D; ;
Routes of; administration	Oral
Drug class	Potassium-sparing diuretic
ATC code	C03DA05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide;
CAS Number	1050477-31-0;
PubChem CID	60150535;
DrugBank	DB16165;
ChemSpider	28669387;
UNII	DE2O63YV8R;
KEGG	D10633;
ChEMBL	ChEMBL2181927;
CompTox Dashboard (EPA)	DTXSID10146928 ;
ECHA InfoCard	100.247.614
Chemical and physical data
Formula	C21H22N4O3
Molar mass	378.432 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES NC(=O)C1=C(C)Nc2c(C)cnc(OCC)c2[C@@H]1c3ccc(C#N)cc3OC;
	InChI InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1; Key:BTBHLEZXCOBLCY-QGZVFWFLSA-N;

Finerenone, marketed under the brand name Kerendia among others, is a medication used to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal, non-fatal myocardial infarctions, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. In the United States, it is also approved to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater. Finerenone is a non-steroidal mineralocorticoid receptor antagonist. It is taken orally (swallowed by mouth).

Common side effects include abnormally high levels of potassium in the bloodstream, abnormally low levels of sodium in the bloodstream, and abnormally low blood pressure.

Finerenone was approved for medical use in the United States in July 2021, and in the European Union in February 2022. The US Food and Drug Administration considers it to be a first-in-class medication.